Lindström Anna, Ohlis Anna, Huigen Marleen, Nijhuis Monique, Berglund Torsten, Bratt Göran, Sandström Eric, Albert Jan
Department of Virology, Immunology and Vaccinology, Swedish Institute for Infectious Disease Control, Solna, Sweden.
Antivir Ther. 2006;11(8):1031-9.
To investigate the prevalence of HIV-1 with major drug resistance-associated mutations among 261 men who have sex with men (MSM) who were newly diagnosed as HIV-1-infected at Venhälsan, Stockholm, between 1992-2002.
Major resistance-associated mutations were identified using an in-house method on stored plasma samples collected within 6 months of diagnosis. Additional samples were investigated from selected patients. Phylogenetic tree analyses were used to study evolutionary relationships between the viruses. Epidemiological data were retrieved from the partner notification investigations and the medical records.
Informed consent as well as results from the resistance test were available for 201 out of 261 patients (77%) diagnosed during 1992-2002. Viruses from 28 of these 201 patients (14%) displayed major resistance-associated mutations; 27 of these viruses displayed only zidovudine/stavudine resistance-associated mutations. None of the patients displayed resistance mutations to protease inhibitors. The prevalence of resistance-associated mutations decreased over time; 20% in 1992-1996 versus 9% in 1997-2002 (P=0.04). A transmission cluster involving six patients with a singleton M41L mutation was identified. These viruses were phenotypically sensitive to zidovudine and stavudine. The M41L mutation, as well as most other resistance mutations, was stable for many years after transmission and may have been fixated by other putative compensatory mutations.
In this Swedish population of MSM with newly diagnosed HIV-1 infection, the prevalence of resistance-associated mutations decreased over time. Reversion of resistance-associated mutations following transmission was slow and incomplete. A large transmission cluster with an interesting M41L singleton mutation was also observed.
调查1992年至2002年间在斯德哥尔摩Venhälsan新诊断为HIV-1感染的261名男男性行为者(MSM)中携带主要耐药相关突变的HIV-1的流行情况。
采用内部方法对诊断后6个月内采集的储存血浆样本进行主要耐药相关突变鉴定。对部分选定患者的额外样本进行了研究。利用系统发育树分析来研究病毒之间的进化关系。从性伴告知调查和病历中获取流行病学数据。
1992年至2002年诊断的261名患者中有201名(77%)获得了知情同意并得到了耐药检测结果。这201名患者中的28名(14%)的病毒显示出主要耐药相关突变;其中27种病毒仅显示齐多夫定/司他夫定耐药相关突变。没有患者显示对蛋白酶抑制剂的耐药突变。耐药相关突变的流行率随时间下降;1992 - 1996年为20%,而1997 - 2002年为9%(P = 0.04)。识别出一个涉及6名携带单一M41L突变患者的传播簇。这些病毒在表型上对齐多夫定和司他夫定敏感。M41L突变以及大多数其他耐药突变在传播后多年保持稳定,可能已被其他假定的补偿性突变固定。
在这个新诊断为HIV-1感染的瑞典男男性行为者群体中,耐药相关突变的流行率随时间下降。传播后耐药相关突变的逆转缓慢且不完全。还观察到一个具有有趣的M41L单一突变的大型传播簇。